Ramucirumab

Ramucirumab is indicated for the treatment of gastric cancer, colorectal cancer, non-small cell lung cancer, and hepatocellular carcinoma.

Under the European Union approval, NSCLC therapy with ramucirumab is contraindicated when there is tumor cavitation, or if major vessels are involved.{{cite web |url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002829/WC500180724.pdf |title=Cyramza: EPAR – Product Information |date=21 January 2015 |publisher=European Medicines Agency |access-date=6 May 2017 |archive-date=30 April 2018 |archive-url=https://web.archive.org/web/20180430045421/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002829/WC500180724.pdf |url-status=dead }}{{cite book |title=Austria-Codex |editor=Haberfeld, H |publisher=Österreichischer Apothekerverlag |location=Vienna |year=2017 |at=Cyramza 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung |language=German}}

The most common adverse effects in a study investigating ramucirumab monotherapy were diarrhea (14% of patients, as compared to 9% under placebo), hyponatraemia (low blood sodium levels; 6% versus 2%), headache (9% versus 3%), and high blood pressure (16% versus 8%).

Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.

In April 2014, the US Food and Drug Administration (FDA) approved ramucirumab as a single-agent treatment for advanced gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy. The approval was based on the results of the REGARD trial, a phase III, international, randomized, double-blind, placebo-controlled study, that evaluated the safety and efficacy of ramucirumab combinated with best supportive care versus placebo.{{cite journal | vauthors = Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J | title = Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | journal = Lancet | volume = 383 | issue = 9911 | pages = 31–39 | date = January 2014 | pmid = 24094768 | doi = 10.1016/s0140-6736(13)61719-5 | s2cid = 41960459 }} This trial has been criticised for its use of a placebo control arm, which does not reflect standard of care in most Western countries.{{cite journal | vauthors = Gyawali B | title = Low-value practices in oncology contributing to financial toxicity | journal = ecancermedicalscience | volume = 11 | pages = 727 | year = 2017 | pmid = 28386297 | pmc = 5365336 | doi = 10.3332/ecancer.2017.727 }}

Ramucirumab has also been studied in combination with paclitaxel (a type of chemotherapy) and received additional FDA approval on 5 November 2014 as a treatment for people with advanced gastric cancer or GEJ adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-based chemotherapy. The approval was based on the results of the RAINBOW trial, that compared ramucirumab plus paclitaxel or paclitaxel alone.{{cite journal | vauthors = Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A | title = Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | journal = The Lancet. Oncology | volume = 15 | issue = 11 | pages = 1224–1235 | date = October 2014 | pmid = 25240821 | doi = 10.1016/S1470-2045(14)70420-6 }}

In December 2014, the FDA approved ramucirumab in combination with docetaxel for treatment of metastatic non-small-cell lung carcinoma (NSCLC) with disease progression during or after first-line platinum-containing chemotherapy. The approval was based on REVEL trial.{{cite journal | vauthors = Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M | title = Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial | journal = Lancet | volume = 384 | issue = 9944 | pages = 665–673 | date = August 2014 | pmid = 24933332 | doi = 10.1016/S0140-6736(14)60845-X | s2cid = 5078660 }}

In April 2015, ramucirumab was approved by FDA for the treatment of people with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and fluoropyrimidine. The approval was based on the results of the RAISE trial, a phase III study, which compared ramucirumab plus irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) to FOLFIRI alone.{{Cite journal |vauthors=Tabernero J, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P |doi=10.1200/jco.2015.33.3_suppl.512 |title=RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp) |journal=Journal of Clinical Oncology |volume=33 |issue=3_suppl |pages=512 |year=2015}}

In May 2019, ramucirumab was approved by FDA as a single agent treatment for hepatocellular carcinoma (HCC) in people who have an alpha fetoprotein (AFP) of > 400 ng/mL and have been previously treated with sorafenib.{{Cite web |date=10 May 2019 |title=FDA approves ramucirumab for hepatocellular carcinoma |url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma |publisher=U.S. Food and Drug Administration (FDA) }} The approval was based on REACH-2 (NCT02435433), a multinational, randomized, double-blind, placebo-controlled, multicenter study in participants with advanced HCC with AFP > 400 ng/mL who had disease progression on or after sorafenib or who were intolerant. The estimated median overall survival (OS) was 8.5 months (7.0-10.6 months) for participants receiving ramucirumab and 7.3 months (5.4-9.1 months) for those receiving placebo.

In September 2013, the manufacturer Eli Lilly announced that its phase III study for ramucirumab failed to hit its primary endpoint on progression-free survival among women with metastatic breast cancer.{{ClinicalTrialsGov|NCT00703326|Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer}}{{cite web |first=John |last=Carroll |name-list-style=vanc |date=26 September 2013 |title=In another stinging setback, Eli Lilly's ramucirumab fails PhIII breast cancer study |url=http://www.fiercebiotech.com/story/another-stinging-setback-eli-lillys-ramucirumab-fails-phiii-breast-cancer-s/2013-09-26 |access-date=27 September 2013}}

In June 2014, a phase III trial of the drug reported it failed to improve overall survival in liver cancer.{{cite web |first=Alex |last=Philippidis |name-list-style=vanc |title=Lilly's Cyramza Fails Phase III Trial in Liver Cancer |url=http://www.genengnews.com/gen-news-highlights/lilly-s-cyramza-fails-phase-iii-trial-in-liver-cancer/81249964/ |work=Genetic Engineering & Biotechnology News |access-date=12 June 2014 |archive-date=9 April 2016 |archive-url=https://web.archive.org/web/20160409002732/http://www.genengnews.com/gen-news-highlights/lilly-s-cyramza-fails-phase-iii-trial-in-liver-cancer/81249964/ |url-status=dead }}

In February 2016, it was reported that a phase II trial of adding ramucirumab to docetaxel improved progression-free survival (PFS) compared with docetaxel alone in locally advanced or metastatic urothelial carcinoma.{{cite web |first=Dave |last=Levitan |name-list-style=vanc |url=http://www.cancernetwork.com/bladder-cancer/ramucirumab-added-docetaxel-extends-pfs-urothelial-carcinoma |title=Added to Docetaxel Extends PFS in Urothelial Carcinoma |date=February 2016 |work=Cancer Network |access-date=4 March 2016 |archive-date=2 March 2020 |archive-url=https://web.archive.org/web/20200302021919/https://www.cancernetwork.com/bladder-cancer/ramucirumab-added-docetaxel-extends-pfs-urothelial-carcinoma |url-status=dead }} It is being studied in the RANGE phase III trial for this indication.{{ClinicalTrialsGov|NCT02426125|A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)}}

Between 2016 and 2018, 26 hospitals in Italy conducted a multicenter, randomized, double-blind, placebo-controlled, phase II trial to evaluate the safety and effectiveness of the anti-VEGFR-2 antibody ramucirumab combined with gemcitabine in participants with pretreated  pleural mesothelioma. Combining ramucirumab to standard second line gemcitabine significantly improved overall survival after failure of first-line chemotherapy, with a favorable safety profile.{{cite journal | vauthors = Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL | title = Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial | journal = The Lancet. Oncology | volume = 22 | issue = 10 | pages = 1438–1447 | date = October 2021 | pmid = 34499874 | doi = 10.1016/S1470-2045(21)00404-6 | s2cid = 237471286 }}

{{reflist}}

{{Targeted cancer therapeutic agents}}

{{Monoclonals for tumors}}

{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}

{{Growth factor receptor modulators}}

{{Eli Lilly and Company}}

{{Portal bar | Medicine}}

{{Authority control}}

Category:Monoclonal antibodies

Category:Angiogenesis inhibitors

Category:Monoclonal antibodies for tumors

Category:Drugs developed by Eli Lilly and Company